Suchergebnisse - "Zonder, Jeffrey A"

PubPharm (72)

1

INSURE : a pooled analysis of ixazomib-lenalidomide-dexamethasone for relapsed/refractory myeloma in routine practice

enthalten in: Future oncology (London, England) | 2024

von Leleu, X. | Lee, H. | Zonder, J. | +10

2

Real-world multiple myeloma risk factors and outcomes by non-Hispanic Black/African American and non-Hispanic White race/ethnicity in the United States

enthalten in: Haematologica | 2023

von Buck, T. | Hartley-Brown, M. | Efebera, Y. | +5

3

Birtamimab plus standard of care in light-chain amyloidosis : the phase 3 randomized placebo-controlled VITAL trial

enthalten in: Blood | 2023

von Gertz, M. | Cohen, A. | Comenzo, R. | +16

CommentIn: Blood. 2023 Oct 5;142(14):1178-1180. - PMID 37796521

4

Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients

enthalten in: Clinical lymphoma, myeloma & leukemia | 2023

von Thompson, M. | Boccadoro, M. | Leleu, X. | +26

5

Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS) : interim analysis of a randomised, open-label, phase 3 trial

enthalten in: The Lancet. Oncology | 2023

von Dytfeld, D. | Wróbel, T. | Jamroziak, K. | +30

CommentIn: Lancet Oncol. 2023 Feb;24(2):118-119. - PMID 36642082

6

Birtamimab plus standard of care in light-chain amyloidosis : the phase 3 randomized placebo-controlled VITAL trial

enthalten in: Blood | October 5, 2023

von Gertz, M. | Cohen, A. | Comenzo, R. | +16

7

Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma

enthalten in: The New England journal of medicine | 2022

von Richardson, P. | Jacobus, S. | Weller, E. | +125

CommentIn: Expert Rev Hematol. 2023 Jul-Dec;16(8):561-563. - PMID 37334674

8

The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma

enthalten in: Nature communications | 2022

von Vo, J. | Wu, Y. | Mishler, J. | +37

9

Filanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple myeloma

enthalten in: Cancer medicine | 2022

von Pan, D. | Kaufman, J. | Htut, M. | +10

10

Preferences and Priorities for Relapsed Multiple Myeloma Treatments Among Patients and Caregivers in the United States

enthalten in: Patient preference and adherence | 2022

von Auclair, D. | Mansfield, C. | Fiala, M. | +10

1
2
3
4
5
6
7
8
Nächster »
[8]